Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075846 | 0.72 | MEN1 (0.55) | POLBALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL10977480 | 0.71 | TSHR (0.37) | TDP1TSHRGAACYP3A4CYP2C9 | |
| SCHEMBL3772237 | 0.70 | TSHR (0.42) | TDP1TSHRGAACYP3A4CYP2C9 | |
| SCHEMBL27170476 | 0.70 | TDP1 (0.51) | TDP1TSHRGAACYP2C9CYP2C19 | |
| SCHEMBL371407 | 0.69 | MEN1 (0.35) | TDP1TSHRGAACYP3A4CYP2C9 | |
| SCHEMBL9723381 | 0.68 | TSHR (0.39) | TDP1TSHRGAACYP3A4CYP2C9 | |
| SCHEMBL8604479 | 0.67 | TSHR (0.35) | TDP1TSHR | |
| SCHEMBL31520565 | 0.67 | TDP1 (0.38) | TDP1TSHRTP53 | |
| SCHEMBL11819542 | 0.66 | POLB (0.38) | TDP1TSHRGAAPOLBTP53 | |
| SCHEMBL11819552 | 0.66 | POLB (0.38) | TDP1TSHRGAAPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687635-B2 | Metal complexes useful in metathesis and other reactions | TELENE S.A.S. (FR) | 2010-03-30 | — | — | US | disclosed |
| EP-1743899-A1 | Metal complexes for use in metathesis, atom transfer radical reactions, addition polymerisation and vinylation reactions, methods and intermediates for making them | Universiteit Gent (BE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1468004-B1 | METAL COMPLEXES FOR USE IN METATHESIS | UNIV GENT (BE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050043541-A1 | Metal complexes useful in metathesis and other reactions | RIMTEC CORPORATION (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1468004-A1 | METAL COMPLEXES FOR USE IN METATHESIS | Universiteit Gent (BE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062253-A1 | METAL COMPLEXES FOR USE IN METATHESIS | UNIVERSITEIT GENT (BE) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043541-A1 | Metal complexes useful in metathesis and other reactions | TST, ETFA, TTPA | TDP1 2078/4885TSHR 2092/4885GAA 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.